Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1556669
This article is part of the Research Topic Innovative Approaches in Glioma Therapy: Exploring New Therapeutic Frontiers View all 3 articles

Photodynamic therapy and tumor-treating fields therapy for newly diagnosed glioblastoma

Provisionally accepted
Shinjiro Fukami Shinjiro Fukami 1*Kenta Nagai Kenta Nagai 1Sho Onodera Sho Onodera 1Yuki Saito Yuki Saito 1Jiro Akimoto Jiro Akimoto 1,2Michihiro Kohno Michihiro Kohno 1
  • 1 Tokyo Medical University, Tokyo, Japan
  • 2 Kohsei Chuo General Hospital, Tokyo, Japan

The final, formatted version of the article will be published soon.

    Introduction and purpose: Various treatment methods, including photodynamic therapy (PDT), are used for glioblastoma (GBM), which is an intractable tumor. Our therapeutic strategy for glioblastoma has been based on resection (if possible), and PDT. On the other hand, after tumor-treating fields therapy (TTF) became available, we have actively recommended it to our patients who are eligible for it. In this report, we describe the clinical characteristics and disease course of glioblastoma patients treated by PDT + TTF at our hospital. Methods: A total of 14 patients with newly diagnosed glioblastoma, who underwent PDT + TTF from the time of insurance coverage of TTF were analyzed. The median age of the patients was 48 (30–73) years. There were 10 men and 4 women, with a high prevalence of younger men. Results: The average duration of TTF was 8.9 (1–19) months, and the main reasons for its discontinuation were recurrence of the tumor and scalp problems. The median progression-free survival of the 14 patients who underwent PDT + TTF was 13.4 months, which tended to be longer than that of the 30 patients who underwent PDT without TTF (11 months). Of the 10 patients who relapsed, 2 had local recurrence and 8 had distant or disseminated recurrence. Two patients with local recurrence underwent repeat resection together with PDT. To date, the prognosis for patient survival of PDT + TTF appears favorable, with 6 patients surviving for more than 2 years. Conclusion: PDT + TTF treatment for newly diagnosed glioblastoma can be performed without any major adverse events, although there are some problems with the continuation of TTF, such as scalp problems and its high cost. More patients who underwent PDT + TTF relapsed with distant and/or disseminated recurrence than local recurrence, suggesting that this treatment strategy targets local recurrence. Our results demonstrate that combination therapy for newly diagnosed glioblastoma with PDT + TTF may prolong the time to recurrence and improve survival outcomes of patients, although the data in this study are preliminary.

    Keywords: Glioblastoma, Photodynamic therapy, Talaporfin sodium, tumor-treating fields therapy, newly diagnosed, prognosis

    Received: 07 Jan 2025; Accepted: 05 Feb 2025.

    Copyright: © 2025 Fukami, Nagai, Onodera, Saito, Akimoto and Kohno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shinjiro Fukami, Tokyo Medical University, Tokyo, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.